GlycoMimetics, Inc.
(NASDAQ : GLYC)

( )
GLYC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.71%194.081.3%$537.24m
GILDGilead Sciences, Inc.
-0.96%65.880.9%$360.40m
ALXNAlexion Pharmaceuticals, Inc.
1.06%108.542.0%$335.82m
ILMNIllumina, Inc.
-0.01%300.893.5%$306.54m
BIIBBiogen Inc.
-0.22%236.121.3%$297.02m
CELGCelgene Corporation
-0.02%98.381.3%$285.49m
SRPTSarepta Therapeutics, Inc.
1.19%87.0214.7%$185.67m
VRTXVertex Pharmaceuticals Incorporated
1.49%177.551.9%$174.68m
AAgilent Technologies, Inc.
-1.01%77.111.6%$173.31m
REGNRegeneron Pharmaceuticals, Inc.
1.52%285.892.6%$171.19m
EXASExact Sciences Corporation
-2.16%104.4124.1%$131.85m
ACADACADIA Pharmaceuticals Inc.
8.80%44.0113.9%$117.45m
INCYIncyte Corporation
2.50%78.342.5%$85.37m
BMRNBioMarin Pharmaceutical Inc.
2.15%74.214.3%$70.34m
IONSIonis Pharmaceuticals, Inc.
-1.62%65.138.2%$63.52m

Company Profile

GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.